S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:MGNX

MacroGenics Stock Forecast, Price & News

$18.77
-0.88 (-4.48%)
(As of 11/26/2021 04:00 PM ET)
Add
Compare
Today's Range
$18.29
$19.67
50-Day Range
$18.29
$21.88
52-Week Range
$17.29
$36.48
Volume
352,836 shs
Average Volume
719,973 shs
Market Capitalization
$1.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.08
30 days | 90 days | 365 days | Advanced Chart
Receive MGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.


MacroGenics logo

About MacroGenics

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Headlines

MacroGenics (NASDAQ:MGNX) Shares Gap Down to $18.29
November 23, 2021 |  americanbankingnews.com
MacroGenics (NASDAQ:MGNX) Hits New 12-Month Low at $17.29
November 19, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MGNX
Employees
370
Year Founded
N/A

Sales & Book Value

Annual Sales
$104.88 million
Book Value
$4.76 per share

Profitability

Net Income
$-129.74 million
Net Margins
-126.03%
Pretax Margin
-126.03%

Debt

Price-To-Earnings

Miscellaneous

Free Float
56,419,000
Market Cap
$1.15 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Today
11/27/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/24/2022

MarketRank

Overall MarketRank

2.01 out of 5 stars

Medical Sector

598th out of 1,391 stocks

Pharmaceutical Preparations Industry

277th out of 669 stocks

Analyst Opinion: 3.4Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












MacroGenics (NASDAQ:MGNX) Frequently Asked Questions

Is MacroGenics a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 1 sell rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MacroGenics stock.
View analyst ratings for MacroGenics
or view top-rated stocks.

How has MacroGenics' stock price been impacted by Coronavirus (COVID-19)?

MacroGenics' stock was trading at $6.49 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MGNX shares have increased by 189.2% and is now trading at $18.77.
View which stocks have been most impacted by COVID-19
.

When is MacroGenics' next earnings date?

MacroGenics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for MacroGenics
.

How were MacroGenics' earnings last quarter?

MacroGenics, Inc. (NASDAQ:MGNX) released its quarterly earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.23. MacroGenics had a negative net margin of 126.03% and a negative trailing twelve-month return on equity of 46.52%. During the same quarter last year, the business earned ($0.66) EPS.
View MacroGenics' earnings history
.

What price target have analysts set for MGNX?

8 brokers have issued 12-month price objectives for MacroGenics' shares. Their forecasts range from $17.00 to $41.00. On average, they anticipate MacroGenics' stock price to reach $34.29 in the next twelve months. This suggests a possible upside of 82.7% from the stock's current price.
View analysts' price targets for MacroGenics
or view top-rated stocks among Wall Street analysts.

Who are MacroGenics' key executives?

MacroGenics' management team includes the following people:
  • Scott E. Koenig, President, Chief Executive Officer & Director
  • James Karrels, Chief Financial Officer, Secretary & Senior VP
  • Ezio Bonvini, Chief Scientific Officer & Senior VP-Research
  • Stephen L. Eck, Chief Medical Officer & SVP-Clinical Development
  • Lynn Cilinski, Treasurer, Vice President & Controller

What is Scott Koenig's approval rating as MacroGenics' CEO?

12 employees have rated MacroGenics CEO Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among MacroGenics' employees.

What other stocks do shareholders of MacroGenics own?

What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

Who are MacroGenics' major shareholders?

MacroGenics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bellevue Group AG (13.95%), BlackRock Inc. (8.75%), Wasatch Advisors Inc. (7.05%), RTW Investments LP (6.49%), Victory Capital Management Inc. (3.22%) and Dimensional Fund Advisors LP (1.99%). Company insiders that own MacroGenics stock include Eric Blasius Risser, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Kenneth Galbraith, Target N V Biotech and Thomas Spitznagel.
View institutional ownership trends for MacroGenics
.

Which major investors are selling MacroGenics stock?

MGNX stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC, BlackRock Inc., Morgan Stanley, Two Sigma Advisers LP, Panagora Asset Management Inc., Opaleye Management Inc., Dimensional Fund Advisors LP, and Citigroup Inc.. Company insiders that have sold MacroGenics company stock in the last year include Eric Blasius Risser, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, and Thomas Spitznagel.
View insider buying and selling activity for MacroGenics
or view top insider-selling stocks.

Which major investors are buying MacroGenics stock?

MGNX stock was acquired by a variety of institutional investors in the last quarter, including RTW Investments LP, Bellevue Group AG, Point72 Asset Management L.P., Victory Capital Management Inc., Wasatch Advisors Inc., Rock Springs Capital Management LP, Integral Health Asset Management LLC, and Goldman Sachs Group Inc..
View insider buying and selling activity for MacroGenics
or or view top insider-buying stocks.

How do I buy shares of MacroGenics?

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MacroGenics' stock price today?

One share of MGNX stock can currently be purchased for approximately $18.77.

How much money does MacroGenics make?

MacroGenics has a market capitalization of $1.15 billion and generates $104.88 million in revenue each year. The biopharmaceutical company earns $-129.74 million in net income (profit) each year or ($2.40) on an earnings per share basis.

How many employees does MacroGenics have?

MacroGenics employs 370 workers across the globe.

What is MacroGenics' official website?

The official website for MacroGenics is www.macrogenics.com.

Where are MacroGenics' headquarters?

MacroGenics is headquartered at 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850.

How can I contact MacroGenics?

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at (301) 251-5172, via email at [email protected], or via fax at 301-251-5321.


This page was last updated on 11/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.